Background: Long COVID (LC) is characterized by persistent symptoms at least 3 months after a SARS-COV-2 infection. LC has been associated with fungal translocation, gut dysfunction, and enhanced systemic inflammation. Currently, there is no approved treatment for this condition. The anti-inflammatory effect of vitamins K2 and D3 was shown to help attenuate the course of acute COVID-19 infection. Objective and hypothesis: This trial aims to investigate the effects of vitamins K2/D3 on LC symptoms, as well as gut and inflammatory markers, in people with established long COVID. Our hypothesis is that by attenuating systemic inflammation, vitamins K2/D3 will improve long COVID symptoms. Methods: This single-site randomized controlled study enrolled adults experiencing ≥2 moderate LC symptoms at least 3 months after a COVID-19 infection. The RECOVER Long COVID Research Index and number and type of LC symptoms were considered. Participants were randomized 2:1 to daily 240 µg K2 (pure MK-7 form) and 2000 UI vitamin D3 or standard of care (SOC) for 24 weeks. The endpoints were changes in symptomatology and in select inflammatory, metabolic, and gut biomarkers at 24 weeks. Results: We enrolled 151 participants (n = 98 received vit K2/D3 and 53 received SOC). The median age was 46 years; 71% were female and 29% were non-white. Baseline demographics were balanced between groups. At 24 weeks, the active treatment group only had a sharp increase in 25(OH) D, indicating good treatment adherence. In the vitamin K2/D3 arm, there was a 7.1% decrease in the proportion who had an LC Index ≥12 (vs. a 7.2% increase in the SOC group; p = 0.01). The average number of LC symptoms remained stable in the vitamin K2/D3 arm but increased in the SOC arm (p = 0.03). Additionally, reductions in oxidized LDL, inflammatory markers sTNF-RI and sCD163, and fungal translocation marker (1,3)-β-d-glucan were observed in the vitamin K2/D3 arm compared to the SOC arm (p < 0.01) over 24 weeks. Conclusions: Vitamins K2/D3 improved the RECOVER Long COVID Index, the number of LC symptoms, and several gut and inflammatory markers. Vitamins K2/D3 provide a promising safe intervention for people suffering from long COVID.
Background: People with human immunodeficiency virus (HIV, PWH) are at higher risk for visceral adiposity, enhanced inflammation, and cognitive decline than controls who do not have HIV. We previously demonstrated that PWH with lipohypertrophy had a decrease in weight, visceral adipose tissue, and several inflammatory markers after receiving semaglutide, a glucagon-like peptide-1 receptor agonist. Our aim was to investigate the effect of semaglutide on cognitive function in PWH and the possible mediation of this effect by changes in adiposity or inflammation. Methods: In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo. The primary outcome was the change in cognitive function at 32 weeks. Secondary measures included changes in body composition and inflammatory markers. Causal mediation analysis assessed semaglutide's direct and indirect effects on Cognivue scores through changes in adiposity and inflammation. Results: 108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years. Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively). After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05). Semaglutide's total natural direct effect maintained a positive effect on the visuospatial score while accounting for potential changes in high-sensitivity C-reactive protein and soluble CD163 levels (P = .04). Conclusions: Semaglutide may have a beneficial impact on visuospatial cognitive function in PWH through its effect on inflammation. Clinical Trials Registration . NCT04019197.
Data are limited for assessing the effect of COVID infection on endothelial function, pre- and post-pandemic. The objective of this study was to assess changes in pre-pandemic cardiovascular parameters after COVID-19 infection. This prospective cohort study used EndoPAT2000 Itamar Medical Ltd., Caesarea, Israel, to measure the augmentation index (AI; arterial elasticity) and reactive hyperemic index (RHI; endothelial function). Markers of endothelial function, inflammation, and gut integrity were collected at pre- and post-pandemic visits. COVID-negative and COVID-positive participants were matched on pre-pandemic covariates, and AI ≥ 5.0 was defined as having worse AI. Among the 156 participants, 50% had documented COVID-19 infection. Groups were balanced (p > 0.05) on pre-pandemic characteristics. Increases in oxLDL (p = 0.03) were observed in the COVID-positive group, and COVID infection had a negative effect on inflammatory markers (sVCAM-1, sTNF-RI, sTNF-RII, sCD14) and gut integrity (I-FABP, BDG) compared to COVID-negative participants (p < 0.05). There was a 16.7% (p = 0.02) increase in the proportion of COVID-positive participants with AI ≥ 5.0, without a significant change (p = 0.09) among the COVID-negative group. COVID-positive status, female sex, and higher IL-6 and sCD163 were associated (p < 0.05) with an increase in having worse AI. COVID infection is independently associated with arterial stiffness. For COVID survivors, female sex and higher markers of inflammation were associated with arterial stiffness.
Background: Low levels of zinc are prevalent in patients living with HIV and are associated with higher morbidity. Zinc has major immunomodulatory effects. This study aimed to assess the effect of zinc supplementation on inflammatory and gut integrity markers and on zinc levels among HIV patients with zinc deficiency. Methods: This was a double-blind randomized placebo-controlled trial assessing the efficacy and safety of zinc supplementation on inflammation and gut markers in people with HIV (PWH) ≥ 18 years old, on stable antiretroviral therapy (ART) with undetectable HIV-1 viral load, and with zinc levels of ≤0.75 mg/L. Participants were randomized 2:1 to zinc gluconate tablets at a dose of 90 mg of elemental zinc or a matching placebo daily for 24 weeks. At baseline and at week 24, we measured plasma levels of zinc and markers of inflammation and gut barrier integrity. Results: Among the 95 participants enrolled in this study, 74% were male, and 65% were non-white, with a median CD4 count of 722 cells/μL. The primary analysis showed an increase in zinc levels in the active group. A decrease in the monocyte activation marker soluble CD14 was observed in the treatment group at −56.31 ng/mL (−263.24; 134.19), compared to an increase in the placebo group of 101.71 ng/mL (−90.50; 243.20); p = 0.021. The stratified analysis showed that the group with the lowest zinc levels at baseline had the greatest improvements in soluble CD14 levels during zinc supplementation. No changes were seen in other inflammation markers or gut integrity markers. Conclusions: This is the most comprehensive study on the effect of zinc supplementation in PWH on inflammatory and gut integrity markers. Decreases were seen in the monocyte activation marker sCD14. In the contemporary HIV era with potent effective therapies, suppressed viremia, and high CD4 cells, zinc supplementation does not offer consistent benefits on inflammation.
19 September 2025 in Open Forum Infectious Diseases
Background: While emerging evidence suggests a potential link between COVID-19 and cognitive impairment, there is a lack of prospective longitudinal research that objectively assesses cognitive outcomes after SARS-CoV-2 infection. This study aims to evaluate changes in cognitive function following COVID-19 in a group of individuals with baseline pre-infectious cognitive assessments. Methods: In this cohort study, cognitive function was objectively measured using the computerized Cognivue Clarity® device. All participants who had available Cognivue® testing were followed with a second Cognivue® assessment ∼1 year later. Based on whether they contracted COVID-19 during this period, participants were categorized into 2 groups according to COVID status. Results: We enrolled 110 participants with a median age of 45 years, 35% females and 46% white; 55 (50%) participants experienced a documented COVID-19 infection during the follow-up period (COVID + group), and the rest remained free of COVID infection (COVID- group). COVID- and COVID + groups were balanced for demographics and duration of follow-up. In the COVID + group, only memory scores changed during follow-up (+3.9; P = .03). The COVID- group showed improvements in the overall Cognivue® score (+2; P = .03), as well as in visuospatial (+1.9; P = .04), executive function (+2.2; P = .02), and naming language (+2.2; P = .01) scores. No statistically significant differences were observed in the overall cognitive score or its subdomains between the 2 groups. Conclusions: In a 45-year-old average population, no decrease in cognitive function was observed 1 year after COVID-19 infection.
Background: COVID-19 has been associated with new-onset diabetes. Prior studies are limited by lack of pre-infection data and preexisting cardiometabolic factors. Clarifying how COVID-19 and long COVID (LC) affect glucose metabolism is essential to guide prevention. We evaluated longitudinal changes in glycemic and cardiometabolic markers after SARS-CoV-2 infection in a prospective cohort with pre-infection baseline measurements. Methods: We included 821 uninfected adult participants from the RECOVER cohort who subsequently developed COVID-19, characterizing participants in their pre-COVID state. Data from up to 12 months post-infection were compared to pre-infection baseline. Participants with preexisting diabetes or pregnancy were excluded. The primary endpoint was change in HbA1c up to 12 months after infection. Analysis was stratified by LC status using the 2024 RECOVER Adult Long COVID Research Index (LCRI). Results: HbA1c remained stable from pre-infection to 12 months post-infection (5.39% vs 5.40%; P = .435). Non-HDL cholesterol and blood pressure decreased modestly, while cystatin C increased slightly; absolute changes were small. High-sensitivity C-reactive protein (hs-CRP), troponin, pro–brain natriuretic peptide (pro-BNP), body mass index, and waist circumference remained stable. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk increased slightly (6.7% to 7.3%; P < .001). Trends were similar across LC groups. New-onset metabolic syndrome incidence was comparable across LC categories (18%-20%), although persistent metabolic syndrome was more frequent in participants with more severe LC. Conclusion: In this cohort with pre-infection baseline data, we found no significant changes in HbA1c or cardiometabolic biomarkers through 12 months after infection, although 10-year ASCVD risk slightly increased. These findings emphasize the importance of longitudinal assessment in differentiating transient physiological changes from persistent cardiometabolic disease after COVID-19.